|
CV THERAPEUTICS I, (CVTX) Stock Research Free Stock Rating
|
|
| |
| Company Profile |
| |
|
CV Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule drugs for the treatment of cardiovascular diseases. The company develops a drug candidate, Ranexa, for the treatment of chronic angina, a debilitating heart condition. It also develops Regadenoson, an A2A-adenosine receptor agonist for use as a pharmacologic agent in cardiac perfusion imaging studies; Tecadenoson, an A1-adenosine receptor agonist for the reduction of rapid heart rate during atrial arrhythmias; and Adentri, an A1-adenosine receptor antagonist for the treatment of congestive heart failure. The company has collaboration with Astellas US LLC to develop and market pharmacologic cardiac stress agents; Biogen Idec, Inc. to develop and commercialize new drugs in the Adentri program based on A1-adensoine receptor antagonist patents and technologies; and Solvay Pharmaceuticals, Inc. to copromote ACEON, an angiotensin converting enzyme inhibitor with tissue activity for the treatment of hypertension. CV Therapeutics was founded in 1990 and is headquartered in Palo Alto, California.
|
CV THERAPEUTICS I Related |
|
CVTX: Summary for CV Therapeutics, Inc. - Yahoo! Finance ... on CV Therapeutics, Inc. ... Analyst Rankings for CV THERAPEUTICS I StarMine(Sun, ... CV THERAPEUTICS INC Files SEC form 10-Q, Quarterly Report EDGAR ...
|
|
CVTX: Profile for CV Therapeutics, Inc. - Yahoo! Finance See the company profile for CV Therapeutics, Inc. (CVTX) including business summary, industry/sector information, number of employees, business summary, corporate ...
|
|
Press Releases "I also want to thank David McCaleb for his enormous contributions to CV ... © 1999-2008, CV Therapeutics, Inc. All rights reserved. ...
|
|
